Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy

Treating breast cancer brain metastases (BCBMs) is challenging. Na(+)/I(−) symporter (NIS) expression in BCBMs would permit their selective targeting with radioiodide ((131)I(−)). We show impressive enhancement of tumor response by combining(131)I(−) with gemcitabine (GEM), a cytotoxic radiosensitiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Renier, Corinne, Do, John, Reyna-Neyra, Andrea, Foster, Deshka, De, Abhijit, Vogel, Hannes, Jeffrey, Stefanie S., Tse, Victor, Carrasco, Nancy, Wapnir, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342383/
https://www.ncbi.nlm.nih.gov/pubmed/27363025
http://dx.doi.org/10.18632/oncotarget.10238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342383/
https://www.ncbi.nlm.nih.gov/pubmed/27363025
http://dx.doi.org/10.18632/oncotarget.10238

Ejemplares similares